163 related articles for article (PubMed ID: 23534877)
1. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.
Farrugia A; Cassar J; Kimber MC; Bansal M; Fischer K; Auserswald G; O'Mahony B; Tolley K; Noone D; Balboni S
Haemophilia; 2013 Jul; 19(4):e228-38. PubMed ID: 23534877
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
Miners AH; Sabin CA; Tolley KH; Lee CA
Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A.
Miners A
Haemophilia; 2009 Jul; 15(4):881-7. PubMed ID: 19473422
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
8. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
9. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.
Castro Jaramillo HE; Moreno Viscaya M; Mejia AE
Int J Technol Assess Health Care; 2016 Jan; 32(5):337-347. PubMed ID: 27919309
[TBL] [Abstract][Full Text] [Related]
10. Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand.
Unim B; Veneziano MA; Boccia A; Ricciardi W; La Torre G
ScientificWorldJournal; 2015; 2015():596164. PubMed ID: 25685844
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
Neovius K; Buesch K; Sandström K; Neovius M
Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
Cortesi PA; Castaman G; Trifirò G; Creazzola SS; Improta G; Mazzaglia G; Molinari AC; Mantovani LG
Thromb Haemost; 2020 Feb; 120(2):216-228. PubMed ID: 31887777
[TBL] [Abstract][Full Text] [Related]
14. Health technology assessment and haemophilia.
Farrugia A; O'Mahony B; Cassar J
Haemophilia; 2012 Mar; 18(2):152-7. PubMed ID: 22335450
[TBL] [Abstract][Full Text] [Related]
15. High-dose hemodialysis versus conventional in-center hemodialysis: a cost-utility analysis from a UK payer perspective.
Liu FX; Treharne C; Arici M; Crowe L; Culleton B
Value Health; 2015 Jan; 18(1):17-24. PubMed ID: 25595230
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of alternative treatments for depression in low-income women.
Beil H; Beeber LS; Schwartz TA; Lewis G
J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy in hemophilia A: a cost-effectiveness analysis.
Machin N; Ragni MV; Smith KJ
Blood Adv; 2018 Jul; 2(14):1792-1798. PubMed ID: 30042145
[TBL] [Abstract][Full Text] [Related]
20. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
